Welcome back, Dr. Sarah Chen
BioPharma Research • researcher@biotech.com
12
Protocols Analyzed
Total analyses completed
72
Avg Risk Score
Across all protocols
147
Risks Identified
Potential amendments prevented
$3.6M
Potential Savings
Amendment costs avoided
Recent Analyses
Phase 3 Oncology Study
Analyzed on 2024-09-14
89
Risk Score
Complete
COVID-19 Vaccine Booster Trial
Analyzed on 2024-09-12
65
Risk Score
Complete
Cardiovascular Device Study
Analyzed on 2024-09-10
78
Risk Score
Complete
Quick Tips
- Upload protocols early in development for maximum benefit
- Review all High and Medium risk sections carefully
- Implement immediate recommendations before study start
Platform Stats
Model Accuracy:75% F1 Score
Validation Dataset:Real Protocols
Average Analysis Time:3-5 minutes
System Status:Operational